These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19472052)

  • 1. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients.
    Cates ME; Jackson CW; Feldman JM; Stimmel AE; Woolley TW
    Community Ment Health J; 2009 Aug; 45(4):251-4. PubMed ID: 19472052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quetiapine for insomnia: A review of the literature.
    Anderson SL; Vande Griend JP
    Am J Health Syst Pharm; 2014 Mar; 71(5):394-402. PubMed ID: 24534594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of low doses of quetiapine when used for insomnia.
    Coe HV; Hong IS
    Ann Pharmacother; 2012 May; 46(5):718-22. PubMed ID: 22510671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents.
    Patel NC; Kistler JS; James EB; Crismon ML
    Pharmacotherapy; 2004 Jul; 24(7):824-30. PubMed ID: 15303445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
    Trivedi MH; Bandelow B; Demyttenaere K; Papakostas GI; Szamosi J; Earley W; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1733-44. PubMed ID: 23673347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials.
    Zhornitsky S; Potvin S; Moteshafi H; Dubreucq S; Rompré PP; Stip E
    Int Clin Psychopharmacol; 2011 Jul; 26(4):183-92. PubMed ID: 21372722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quetiapine for insomnia in Parkinson disease: results from an open-label trial.
    Juri C; Chaná P; Tapia J; Kunstmann C; Parrao T
    Clin Neuropharmacol; 2005; 28(4):185-7. PubMed ID: 16062098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.
    Bauer M; McIntyre RS; Szamosi J; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1755-65. PubMed ID: 23672772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
    Zheng L; Mack WJ; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Stroup TS; Sultzer DL; Tariot PN; Vigen C; Schneider LS
    Am J Psychiatry; 2009 May; 166(5):583-90. PubMed ID: 19369318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of dose escalation of quetiapine in persistent insomnia disorder.
    Cornelis C; Van Gastel A; Dumont G; Coppens V; Sabbe B; Morrens M; Van Den Eede F
    Acta Clin Belg; 2017 Oct; 72(5):346-348. PubMed ID: 27960654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of quetiapine in children and adolescents.
    Masi G; Milone A; Veltri S; Iuliano R; Pfanner C; Pisano S
    Paediatr Drugs; 2015 Apr; 17(2):125-40. PubMed ID: 25686575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions.
    Wine JN; Sanda C; Caballero J
    Ann Pharmacother; 2009 Apr; 43(4):707-13. PubMed ID: 19299326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
    McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
    J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
    Potkin SG; Thyrum PT; Alva G; Bera R; Yeh C; Arvanitis LA
    J Clin Psychopharmacol; 2002 Apr; 22(2):121-30. PubMed ID: 11910256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of quetiapine on sleep in recovering alcohol-dependent subjects: a pilot study.
    Chakravorty S; Hanlon AL; Kuna ST; Ross RJ; Kampman KM; Witte LM; Perlis ML; Oslin DW
    J Clin Psychopharmacol; 2014 Jun; 34(3):350-4. PubMed ID: 24747978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine.
    Naharci MI; Karadurmus N; Demir O; Bozoglu E; Ak M; Doruk H
    Am J Psychiatry; 2011 Feb; 168(2):212-3. PubMed ID: 21297052
    [No Abstract]   [Full Text] [Related]  

  • 20. Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients.
    Rasmussen H; Ebdrup BH; Oranje B; Pinborg LH; Knudsen GM; Glenthøj B
    Int J Neuropsychopharmacol; 2014 Nov; 17(11):1729-36. PubMed ID: 24830305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.